Current and future issues in the manufacturing and development of monoclonal antibodies.

Despite a slow beginning, monoclonal antibodies have had many successes over the past decade. It is important that these successes continue, bringing more products for more indications to market. Although manufacturing is not the most common cause of product failure, product quality issues can delay antibody development. Manufacturing has depended on the triad of process validation, process control and product testing. Applying product knowledge proactively to manufacturing (quality by design) may allow greater flexibility and maintain or improve product quality. An integrated approach to biological characterization is an important aspect of product knowledge. Greater product knowledge also facilitates development in other disciplines. Independent of manufacturing strategy, there are a number of regulatory hurdles in initial and ongoing antibody development. These are described to help prevent unnecessary delays.

[1]  Cuthbert Daniel.  Applications of Statistics to Industrial Experimentation , 1976 .

[2]  A. Velázquez‐Campoy,et al.  Characterization of protein-protein interactions by isothermal titration calorimetry. , 2004, Methods in molecular biology.

[3]  J. O'connor.  The use of peptide mapping for the detection of heterogeneity in recombinant DNA-derived proteins. , 1993, Biologicals : journal of the International Association of Biological Standardization.

[4]  K R Anumula,et al.  High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. , 1998, Glycobiology.

[5]  Kurt Brorson,et al.  Impact of multiple re-use of anion-exchange chromatography media on virus removal. , 2005, Journal of chromatography. A.

[6]  T. Raju,et al.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.

[7]  Michael Karas,et al.  Matrix‐assisted laser desorption ionization mass spectrometry , 1991 .

[8]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[9]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[10]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[11]  A K Patel,et al.  The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.

[12]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[14]  M. Cromwell,et al.  Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. , 1999, Biochemistry.

[15]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[16]  S. Subramaniam,et al.  Three-dimensional electron microscopy at molecular resolution. , 2004, Annual review of biophysics and biomolecular structure.

[17]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[18]  R. Jefferis.  Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[19]  K. Stein.  Overcoming obstacles to monoclonal antibody product development and approval. , 1997, Trends in biotechnology.

[20]  J. Stults.  Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). , 1995, Current opinion in structural biology.

[21]  R. Zhu,et al.  Studying protein aggregation by programmed flow field-flow fractionation using ceramic hollow fibers. , 2005, Analytical chemistry.

[22]  D. Normile,et al.  Mastering Macromolecules , 2002, Science.

[23]  Friedrich Förster,et al.  Computational exploration of structural information from cryo-electron tomograms. , 2004, Current opinion in structural biology.

[24]  M. Regenmortel.  Use of biosensors to characterize recombinant proteins. , 1994 .

[25]  J. Bartlett.  Pharmacodiagnostic Testing in Breast Cancer , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[26]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[27]  Keith L Carson.  Flexibility—the guiding principle for antibody manufacturing , 2005, Nature Biotechnology.

[28]  G Sofer,et al.  Validation of biotechnology products and processes. , 1995, Current opinion in biotechnology.

[29]  J. Hébert,et al.  Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion. Support of Jerne's Network Theory. , 1990, Journal of immunology.

[30]  Noreen R. Gonzales,et al.  Minimizing the Immunogenicity of Antibodies for Clinical Application , 2005, Tumor Biology.

[31]  K. Brorson,et al.  Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. , 2003, Journal of chromatography. A.

[32]  N. Taulier,et al.  Characterization of pH-induced transitions of beta-lactoglobulin: ultrasonic, densimetric, and spectroscopic studies. , 2001, Journal of molecular biology.

[33]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[34]  S L Morrison,et al.  Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.

[35]  E. Hounsell,et al.  HPLC and HPAEC of oligosaccharides and glycopeptides. , 1998, Methods in molecular biology.